Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer

Diane K. Reyes, Kenneth J. Pienta

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of the study was to evaluate the feasibility of utilizing peripheral androgen blockade in men with biochemical recurrent castrate-sensitive prostate cancer. A registration study to track outcomes of men with biochemical recurrent castrate-sensitive prostate cancer treated with peripheral androgen blockade utilizing concomitant administration of finasteride and bicalutamide. Men were on intermittent peripheral blockade for a median 20.2 months, continuous peripheral blockade for a median 6.8 months, intermittent triple dose peripheral androgen blockade for a median 10.7 months, and continuous triple dose peripheral androgen blockade for 4.4 months before failing therapy. Six men (21%) had additional therapies during treatment that included metastasis-directed therapy (5/37, 14%), systemic Lu-177 (2/37, 5%), and salvage RT (1/37, 3%). The median time to progression, which includes time from initiation through all therapies to the initiation of ADT, was 37.6 months (IQR 20–74.7). From the start of PAB, median time to castrate resistance was 49.8 months (IQR 40.9-NR). After starting ADT, median time to castrate resistance was 8.8 months (IQR 4.6–17.7). Our data support the exploration of PAB as a treatment option in carefully selected patients who present with biochemical recurrence after failure of definitive local therapy for prostate cancer.

Original languageEnglish (US)
Article number80
JournalMedical Oncology
Volume38
Issue number7
DOIs
StatePublished - Jul 2021

Keywords

  • Androgen deprivation therapy
  • Bicalutamide
  • Finasteride
  • Peripheral androgen blockade
  • Prostate cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer'. Together they form a unique fingerprint.

Cite this